Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bonkovsky

Showing results (301-310 of 351) with videos related to

Pageof 36
Sort By:
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Gastroenterology|January 24, 2007
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman, Marc G Ghany, Timothy R Morgan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 11, 2014
MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNAHossein Sendi, Marjan Mehrab-Mohseni, David M Foureau, et al.
The American Journal of Medicine|October 17, 2022
Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]Dina Halegoua-DeMarzio, Victor Navarro, Jawad Ahmad, et al.
Controlled Clinical Trials|October 7, 2004
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee, Jules L Dienstag, Karen L Lindsay, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferonAdrian M Di Bisceglie, Anne M Stoddard, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|February 24, 2005
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis CAlan Lee Rothman, Chihiro Morishima, Herbert L Bonkovsky, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trialZachary D Goodman, Anne M Stoddard, Herbert L Bonkovsky, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Pageof 36

Showing results (301-310 of 351) with videos related to

Sort By:
Pageof 36
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Gastroenterology|January 24, 2007
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman, Marc G Ghany, Timothy R Morgan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 11, 2014
MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNAHossein Sendi, Marjan Mehrab-Mohseni, David M Foureau, et al.
The American Journal of Medicine|October 17, 2022
Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]Dina Halegoua-DeMarzio, Victor Navarro, Jawad Ahmad, et al.
Controlled Clinical Trials|October 7, 2004
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee, Jules L Dienstag, Karen L Lindsay, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferonAdrian M Di Bisceglie, Anne M Stoddard, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|February 24, 2005
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis CAlan Lee Rothman, Chihiro Morishima, Herbert L Bonkovsky, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trialZachary D Goodman, Anne M Stoddard, Herbert L Bonkovsky, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Pageof 36